Due to the lack of preclinical models that can faithfully recapitulate this transformation, much of our understanding of NSCLC LUAD to SCLC comes from the studies of clinical samples where patients initially diagnosed with LUAD and treated with EGFR TKIs later relapsed with SCLC tumor [109]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.